R&D The diagnostic odyssey: Challenges and opportunities in tran... Transthyretin amyloidosis (ATTR) is a rarely diagnosed and relentless disease that demands our attention.
R&D When costing and compliance collide Only a few years ago, compliance was the undisputed top priority in the pharmaceutical industry - regardless of cost.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
R&D Looking to early-stage companies for innovation, with Juerge... In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.
R&D Going wide on immune system activation, with Jeffrey Meckler Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.
R&D BIO 2025: Healey shades Trump as she announces $40M in tax i... Massachusetts Governor Maura Healey took shots at the Trump Administration as she announced $40M in life sciences tax incentives at BIO 2025.
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
